State Street Health Care Select Sector SPDR ETF
XLVDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 24, 2026 | $0.66 | 2026-06-22 | 2026-06-22 |
| March 25, 2026 | $0.59 | 2026-03-23 | 2026-03-23 |
| December 24, 2025 | $0.66 | 2025-12-22 | 2025-12-22 |
| September 24, 2025 | $0.62 | 2025-09-22 | 2025-09-22 |
| June 25, 2025 | $0.63 | 2025-06-23 | 2025-06-23 |
Dividends Summary
- Consistent Payer: State Street Health Care Select Sector SPDR ETF has rewarded shareholders with 79 dividend payments over the past 19 years.
- Total Returned Value: Investors who held XLV shares during this period received a total of $26.22 per share in dividend income.
- Latest Payout: The most recent dividend of $0.66/share was paid 24 days ago, on June 24, 2026.
- Yield & Schedule: XLV currently pays dividends quarterly with an annual yield of 1.57%.
- Dividend Growth: Since 2007, the dividend payout has grown by 427.7%, from $0.12 to $0.66.
Company News
The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yiel...
The healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 e...
The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Thera...
AbbVie announced nine-year Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab significantly improved progression-free survival (6.4 years vs 3.2 years) compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients. The fixed-duration combination demonstrated median time to next treatment of 7....
The article compares two healthcare ETFs with different investment strategies: XLV (State Street Health Care Select Sector SPDR ETF) focuses on established healthcare giants with low costs and stable dividends, while PINK (Simplify Health Care ETF) pursues medical innovation through active management and donates profits to charity. PINK delivered...
